Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Mar 19

PMID 30881917

Citations 26

Authors

Yi Miao

L Jeffrey Medeiros

Zijun Y Xu-Monette

Jianyong Li

Ken H Young

Affiliations

Soon will be listed here.

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma worldwide, representing 30-40% of non-Hodgkin lymphomas, and is clinically aggressive. Although more than half of patients with DLBCL are cured by using standard first-line immunochemotherapy, the remaining patients are refractory to the first-line therapy or relapse after complete remission and these patients require novel therapeutic approaches. Understanding the pathogenesis of DLBCL is essential for identifying therapeutic targets to tackle this disease. Cell survival dysregulation, a hallmark of cancer, is a characteristic feature of DLBCL. Intrinsic signaling aberrations, tumor microenvironment dysfunction, and viral factors can all contribute to the cell survival dysregulation in DLBCL. In recent years, several novel drugs that target abnormal cell survival pathways, have been developed and tested in clinical trials of patients with DLBCL. In this review, we discuss cell survival dysregulation, the underlying mechanisms, and how to target abnormal cell survival therapeutically in DLBCL patients.

Citing Articles

SH3GL1-activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B-cell lymphoma.

Duan Z, Wang W, Wang Y, Wang R, Hua W, Shang C Clin Transl Med. 2025; 15(3):e70246.

PMID: 40038872 PMC: 11879899. DOI: 10.1002/ctm2.70246.

Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.

Zhang C, Zhan S, He Y, Pan Z, You Z, Zhu X Front Pharmacol. 2024; 15:1482354.

PMID: 39605902 PMC: 11598492. DOI: 10.3389/fphar.2024.1482354.

In Silico Discovery of a Novel PI3Kδ Inhibitor Incorporating 3,5,7-Trihydroxychroman-4-one Targeting Diffuse Large B-Cell Lymphoma.

Jia W, Liu J, Cheng X, Li X, Ma Y Int J Mol Sci. 2024; 25(20).

PMID: 39457034 PMC: 11508633. DOI: 10.3390/ijms252011250.

Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in spontaneous lymphoblastoid cell lines.

Tam K, Xie J, Au-Yeung R, Chiang A PLoS Pathog. 2024; 20(9):e1012250.

PMID: 39325843 PMC: 11481030. DOI: 10.1371/journal.ppat.1012250.

TCP1 expression alters the ferroptosis sensitivity of diffuse large B-cell lymphoma subtypes by stabilising ACSL4 and influences patient prognosis.

Zhang S, Wang J, Huang G, Xiao X, Xu S, Weng P Cell Death Dis. 2024; 15(8):611.

PMID: 39174525 PMC: 11341815. DOI: 10.1038/s41419-024-07001-0.

References

FREEDMAN D, Wu L, Levine A . Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999; 55(1):96-107. PMC: 11146946. DOI: 10.1007/s000180050273. View

Uchida J, Yasui T, Muraoka M, Kulwichit W, Raab-Traub N, Kikutani H . Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science. 1999; 286(5438):300-3. DOI: 10.1126/science.286.5438.300. View

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

Grossman S . p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem. 2001; 268(10):2773-8. DOI: 10.1046/j.1432-1327.2001.02226.x. View

Zhou P, Levy N, Xie H, Qian L, Lee C, Gascoyne R . MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood. 2001; 97(12):3902-9. DOI: 10.1182/blood.v97.12.3902. View

Eliopoulos A, Young L . LMP1 structure and signal transduction. Semin Cancer Biol. 2001; 11(6):435-44. DOI: 10.1006/scbi.2001.0410. View

Higuchi M, Kieff E, Izumi K . The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines. J Virol. 2001; 76(1):455-9. PMC: 135721. DOI: 10.1128/jvi.76.1.455-459.2002. View

Davis R, Brown K, Siebenlist U, Staudt L . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-74. PMC: 2193582. DOI: 10.1084/jem.194.12.1861. View

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

10.

Cory S, Adams J . The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002; 2(9):647-56. DOI: 10.1038/nrc883. View

11.

Katsumata M, Siegel R, Louie D, Miyashita T, Tsujimoto Y, Nowell P . Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A. 1992; 89(23):11376-80. PMC: 50553. DOI: 10.1073/pnas.89.23.11376. View

12.

Kraus M, Alimzhanov M, Rajewsky N, Rajewsky K . Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004; 117(6):787-800. DOI: 10.1016/j.cell.2004.05.014. View

13.

Phan R, Dalla-Favera R . The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004; 432(7017):635-9. DOI: 10.1038/nature03147. View

14.

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-26. DOI: 10.1200/JCO.2005.09.131. View

15.

Kusumoto S, Kobayashi Y, Sekiguchi N, Tanimoto K, Onishi Y, Yokota Y . Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype". Am J Surg Pathol. 2005; 29(8):1067-73. View

16.

Mainou B, Everly Jr D, Raab-Traub N . Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene. 2005; 24(46):6917-24. DOI: 10.1038/sj.onc.1208846. View

17.

Takagi M, Absalon M, McLure K, Kastan M . Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005; 123(1):49-63. DOI: 10.1016/j.cell.2005.07.034. View

18.

Marmey B, Boix C, Barbaroux J, Dieu-Nosjean M, Diebold J, Audouin J . CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol. 2005; 37(1):68-77. DOI: 10.1016/j.humpath.2005.09.016. View

19.

Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R . Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991; 65(7):1107-15. DOI: 10.1016/0092-8674(91)90007-l. View

20.

Deng X, Gao F, Flagg T, Anderson J, May W . Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol. 2006; 26(12):4421-34. PMC: 1489125. DOI: 10.1128/MCB.01647-05. View